ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (NASDAQ: INHX) announced today that it will host a conference call on Thursday, May 13, 2010 at 9:00 a.m. EDT to review the Company’s first quarter financial results and provide an update on recent corporate developments. The Company will issue a press release regarding its financial results on the same day, prior to the conference call.
To access the conference call, please dial (877) 407-8031 (domestic) or (201) 689-8031 (international). A replay of the call will be available from 11:00 a.m. Eastern Time on May 13th until June 13, 2010 at midnight. To access the replay, please dial (877) 660-6853 (domestic) or (201) 612-7415 (international) and reference the account # 286 and the conference id # 350196. A live audio webcast of the call and the archived webcast will be available in the News and Events section of the Inhibitex website at http://www.inhibitex.com.
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com.
For additional information about the Company, please visit www.inhibitex.com.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
KEYWORDS: United States North America Georgia
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Hospitals Infectious Diseases Pharmaceutical Research Science